ASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)

 Volver  Ver
Investigation of PD‑L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with ventana PD-L1 (SP263) assay and combined positive score (CPS)
 POSTER   09/2020
 Download  Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
PD1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
Safety and efficacy of long-term exposure (LTE) to tislelizumab in chinese patients with advanced solid tumors
 Volver